Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial

被引：0
|
作者：
Bagel, J. [1 ]
Nia, J. [2 ]
Hashim, P. [2 ]
Patekar, M. [3 ]
de Vera, A. [3 ]
Hugot, S. [3 ]
Sheng, K. [4 ]
Xia, S. [5 ]
Gilloteau, I. [3 ]
Blauvelt, A. [6 ]
Lebwohl, M. [2 ]
Bian, M. [7 ]
机构：
[1] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Oregon Med Res Ctr, Portland, OR USA
[7] Novartis Pharmaceut Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] Ixekizumab provides greater cumulative benefits versus ustekinumab over 24 weeks for patients with moderate-to-severe psoriasis in a randomized double-blind phase 3b clinical trial
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Henneges, Carsten
    Shen, Wei
    Shrom, David
    Dossnbach, Martin
    Pinter, Andreas
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB173 - AB173
  • [42] The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
    Bagel, Jerry
    Duffin, Kristina Callis
    Moore, Angela
    Ferris, Laura K.
    Siu, Kimberly
    Steadman, Jennifer
    Kianifard, Farid
    Nyirady, Judit
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 667 - 674
  • [43] Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis The PAUSE Randomized Clinical Trial
    Harris, Kristina M.
    Smilek, Dawn E.
    Byron, Margie
    Lim, Noha
    Barry, William T.
    McNamara, James
    Garcet, Sandra
    Konrad, Robert J.
    Stengelin, Martin
    Bathala, Pradeepthi
    Korman, Neil J.
    Feldman, Steven R.
    Boh, Erin E.
    Barber, Kirk
    Laumann, Anne E.
    Helfrich, Yolanda Rosi
    Krueger, Gerald G.
    Sofen, Howard
    Bissonnette, Robert
    Krueger, James G.
    JAMA DERMATOLOGY, 2021, 157 (11) : 1306 - 1315
  • [44] Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Langley, Richard G.
    Warren, Richard B.
    Lebwohl, Mark
    Elewski, Boni
    Crowley, Jeffrey
    Warham, Rhys
    Kaspar, Markus
    Wiegratz, Susanne
    Ciaravino, Valerie
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB184 - AB184
  • [45] Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
    Landells, Ian
    Marano, Colleen
    Hsu, Ming-Chun
    Li, Shu
    Zhu, Yaowei
    Eichenfield, Lawrence F.
    Hoeger, Peter H.
    Menter, Alan
    Paller, Amy S.
    Taieb, Alain
    Philipp, Sandra
    Szapary, Philippe
    Randazzo, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (04) : 594 - 603
  • [46] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [47] Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
    Soung, Jennifer
    Rosmarin, David
    Ferrer, Anna Lopez
    Lain, Edward
    Rich, Phoebe
    White, Katy
    Staelens, Fabienne
    Szilagyi, Balint
    Deherder, Delphine
    Magnolo, Nina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB128 - AB128
  • [48] Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
    Reich, K.
    Nestle, F. O.
    Papp, K.
    Ortonne, J. -P.
    Wu, Y.
    Bala, M.
    Evans, R.
    Guzzo, C.
    Li, S.
    Dooley, L. T.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (06) : 1161 - 1168
  • [49] Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
    Zhu, Xuejun
    Zheng, Min
    Song, Michael
    Shen, Yaung-Kaung
    Chan, Daphne
    Szapary, Philippe O.
    Wang, Baoxi
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (02) : 166 - 174
  • [50] Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial
    Blauvelt, Andrew
    Lomaga, Mark
    Burge, Russel
    Zhu, Baojin
    Shen, Wei
    Shrom, David
    Dossenbach, Martin
    Pinter, Andreas
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (02) : 141 - 146
12345